AR066544A1 - Metodos de utilizacion de antagonistas de la vasopresina con agentes para quimioterapia con antracina para reducir la cardiotoxicidad y/o aumentar la supervivencia. composicion farmaceutica. - Google Patents
Metodos de utilizacion de antagonistas de la vasopresina con agentes para quimioterapia con antracina para reducir la cardiotoxicidad y/o aumentar la supervivencia. composicion farmaceutica.Info
- Publication number
- AR066544A1 AR066544A1 ARP080102015A ARP080102015A AR066544A1 AR 066544 A1 AR066544 A1 AR 066544A1 AR P080102015 A ARP080102015 A AR P080102015A AR P080102015 A ARP080102015 A AR P080102015A AR 066544 A1 AR066544 A1 AR 066544A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- methods
- vasopresine
- antracine
- antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos para reducir la cardiotoxicidad y/o aumentar la supervivencia del tratamiento con agentes de antraciclina que comprende administrar una cantidad efectiva para uso terapéutico de una composicion que comprende un compuesto antagonista de lavasopresina o una sal aceptable para uso farmacéutico del mismo como un componente activo, administrada en forma simultánea o anterior a la administracion de antraciclinas. Reivindicacion 4: El método de la reivindicacion 1, caracterizado porque elantagonista de la vasopresina es un compuesto representado por la formula (1) donde R1 es un átomo de hidrogeno o un átomo de halogeno, R2 es un grupo hidroxi, o un grupo de la formula: --NR5R6 donde R5 y R6 son iguales o diferentes y son cada unoun átomo de hidrogeno o un grupo alquilo inferior, R3 es un átomo de hidrogeno, un átomo de halogeno, un grupo alquilo inferior, o un grupo alcoxi inferior, R4 es un átomo de halogeno, un grupo alquilo inferior, o un grupo alcoxi inferior, o una salaceptable para uso farmacéutico del mismo. Reivindicacion 7: El método de la reivindicacion 1, caracterizado porque la antraciclina se selecciona del grupo que consiste en daunorubicina, doxorubicina, epirubicina e idarubicina. Reivindicacion 8:El método de la reivindicacion 1, caracterizado porque el antagonista de la vasopresina es tolvaptan.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93808907P | 2007-05-15 | 2007-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066544A1 true AR066544A1 (es) | 2009-08-26 |
Family
ID=40122254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102015A AR066544A1 (es) | 2007-05-15 | 2008-05-13 | Metodos de utilizacion de antagonistas de la vasopresina con agentes para quimioterapia con antracina para reducir la cardiotoxicidad y/o aumentar la supervivencia. composicion farmaceutica. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8372830B2 (es) |
| EP (1) | EP2146721B1 (es) |
| KR (1) | KR101508797B1 (es) |
| CN (2) | CN101808517A (es) |
| AR (1) | AR066544A1 (es) |
| AU (1) | AU2008254273B2 (es) |
| BR (1) | BRPI0811134A2 (es) |
| CA (1) | CA2685186A1 (es) |
| CO (1) | CO6280574A2 (es) |
| CY (1) | CY1114163T1 (es) |
| DK (1) | DK2146721T3 (es) |
| ES (1) | ES2421639T3 (es) |
| HR (1) | HRP20130920T1 (es) |
| IL (1) | IL202094A (es) |
| MX (1) | MX2009012164A (es) |
| MY (1) | MY150682A (es) |
| NZ (1) | NZ581126A (es) |
| PL (1) | PL2146721T3 (es) |
| PT (1) | PT2146721E (es) |
| RU (1) | RU2470643C2 (es) |
| SI (1) | SI2146721T1 (es) |
| TW (1) | TWI428131B (es) |
| UA (1) | UA99914C2 (es) |
| WO (1) | WO2008144269A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011503085A (ja) * | 2007-11-07 | 2011-01-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アンギオテンシン変換酵素阻害剤及びバソプレッシン受容体拮抗薬を含む複合治療 |
| WO2013176955A1 (en) * | 2012-05-21 | 2013-11-28 | The General Hospital Corporation | Cardioprotective compounds, their use with chemotherapy, and methods for identifying them |
| WO2014062888A1 (en) * | 2012-10-18 | 2014-04-24 | University Of South Florida | Compositions and methods for treating stroke |
| US9682983B2 (en) | 2013-03-14 | 2017-06-20 | The Brigham And Women's Hospital, Inc. | BMP inhibitors and methods of use thereof |
| EP2983674A4 (en) | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| WO2015050983A1 (en) * | 2013-10-01 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules |
| WO2016011019A1 (en) | 2014-07-15 | 2016-01-21 | The Brigham And Women's Hospital, Inc. | Compositions and methods for inhibiting bmp |
| WO2017120220A1 (en) | 2016-01-04 | 2017-07-13 | Adepthera Llc | Peptide analogs |
| US11701409B2 (en) | 2016-02-09 | 2023-07-18 | Adepthera Llc | Dosing and use of long-acting CLR/ramp agonists |
| WO2018226875A2 (en) * | 2017-06-07 | 2018-12-13 | University Of Kansas | Methods and medicaments for the treatment of renal cell carcinoma |
| WO2019005623A1 (en) | 2017-06-30 | 2019-01-03 | Adepthera Llc | PEPTIDE ANALOGS |
| TWI737974B (zh) | 2018-04-09 | 2021-09-01 | 美商標徑製藥公司 | 用於治療增生性失調的劑量方案 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US574455A (en) * | 1897-01-05 | Switch-lock | ||
| US5744455A (en) * | 1988-01-27 | 1998-04-28 | New York University | Reduction of anthracycline-induced cardiotoxicity |
| TWI322689B (en) * | 2003-02-24 | 2010-04-01 | Otsuka Pharma Co Ltd | Method for treating severe heart failure and medicament therefor |
-
2008
- 2008-05-12 HR HRP20130920AT patent/HRP20130920T1/hr unknown
- 2008-05-12 MY MYPI20094727 patent/MY150682A/en unknown
- 2008-05-12 RU RU2009146376/15A patent/RU2470643C2/ru not_active IP Right Cessation
- 2008-05-12 NZ NZ581126A patent/NZ581126A/en not_active IP Right Cessation
- 2008-05-12 BR BRPI0811134-0A2A patent/BRPI0811134A2/pt not_active IP Right Cessation
- 2008-05-12 CN CN200880015930A patent/CN101808517A/zh active Pending
- 2008-05-12 US US12/600,145 patent/US8372830B2/en not_active Expired - Fee Related
- 2008-05-12 SI SI200831041T patent/SI2146721T1/sl unknown
- 2008-05-12 ES ES08755284T patent/ES2421639T3/es active Active
- 2008-05-12 CA CA002685186A patent/CA2685186A1/en not_active Abandoned
- 2008-05-12 CN CN201310392696.2A patent/CN103550233A/zh active Pending
- 2008-05-12 KR KR1020097023586A patent/KR101508797B1/ko not_active Expired - Fee Related
- 2008-05-12 MX MX2009012164A patent/MX2009012164A/es active IP Right Grant
- 2008-05-12 UA UAA200912956A patent/UA99914C2/ru unknown
- 2008-05-12 DK DK08755284.0T patent/DK2146721T3/da active
- 2008-05-12 WO PCT/US2008/063374 patent/WO2008144269A2/en not_active Ceased
- 2008-05-12 PL PL08755284T patent/PL2146721T3/pl unknown
- 2008-05-12 PT PT87552840T patent/PT2146721E/pt unknown
- 2008-05-12 AU AU2008254273A patent/AU2008254273B2/en not_active Ceased
- 2008-05-12 EP EP08755284.0A patent/EP2146721B1/en not_active Not-in-force
- 2008-05-13 AR ARP080102015A patent/AR066544A1/es unknown
- 2008-05-14 TW TW097117689A patent/TWI428131B/zh not_active IP Right Cessation
-
2009
- 2009-11-06 CO CO09125771A patent/CO6280574A2/es not_active Application Discontinuation
- 2009-11-12 IL IL202094A patent/IL202094A/en not_active IP Right Cessation
-
2013
- 2013-07-23 CY CY20131100624T patent/CY1114163T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066544A1 (es) | Metodos de utilizacion de antagonistas de la vasopresina con agentes para quimioterapia con antracina para reducir la cardiotoxicidad y/o aumentar la supervivencia. composicion farmaceutica. | |
| JP2020528880A5 (es) | ||
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| AR058620A1 (es) | Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
| AR062068A1 (es) | Sal tartrato de(7)s-7-[(5-fluoro-2-metil-bencil)oxi]-2-[(2r)-2-metilpiperazin-il]-6,7-dihidro-5h-ciclopenta[b]piridina, composiciones farmaceuticas que la contienen, y usos en trastornos asociados fundamentalmente al scn | |
| AR084663A1 (es) | Preparados liofilizados de inhibidores de proteasomas | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| AR081575A1 (es) | Formas de dosificacion oral de bendamustina y su uso terapeutico | |
| AR048502A1 (es) | Sinergia terapeutica de compuestos anti-cancer | |
| AR069244A1 (es) | Metodos para administrar n-( 5- ter- butil- isoxixasol-3-il) -n'- (4(7-(2- morfolin-4-il- etoxi) imidazo (2,1-b) (1,3) benzotiazol -2-il) fenil) urea para tratar una enfermedad proliferante y composicion farmaceutica | |
| AR078224A1 (es) | Composicon para el tratamiento del cancer de prostata | |
| AR096526A1 (es) | Agentes citotóxicos para el tratamiento del cáncer | |
| CA2659537C (en) | Methods and compositions for promoting activity of anti-cancer therapies | |
| CU20090007A6 (es) | Un compuesto farmacéutico y un proceso del mismo | |
| AR081835A1 (es) | Formas de dosificacion oral de bendamustina | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| CA2582452C (en) | Pegylated liposomal doxorubicin in combination with ecteinascidin 743 | |
| DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| MX2009005798A (es) | Recuperacion de apoplejia. | |
| AR078170A1 (es) | Metodos para el tratamiento de tumores cerebrales | |
| DOP2021000073A (es) | Formulación basada en ciclodextrina de un inhibidor de bcl-2 | |
| BR112012009388A2 (pt) | derivados de apogossipolone como agentes anticâncer | |
| WO2007056236A3 (en) | Methods of treating cancer with lipid-based platinum compound formulations administered intravenously |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |